Target intelligence / Profile preview

SYF2 pre-mRNA splicing factor pseudogene 1 (SYF2P1)

Target
SYF2P1
Molecular classification
Other; specifically, processed pseudogene
01

Overview

SYF2 pre-mRNA splicing factor pseudogene 1 (SYF2P1) is a human genomic processed pseudogene derived from the SYF2 gene, which encodes an RNA splicing factor involved in cell cycle regulation and DNA repair. As a pseudogene, SYF2P1 does not produce a functional protein and is generally not regarded as a drug target, enzyme, receptor, or transporter. Pseudogenes such as SYF2P1 can sometimes regulate the expression of their parent genes through transcriptional or post-transcriptional effects (e.g., formation of antisense RNA or competition for microRNA binding), but specific functional or disease-related roles for SYF2P1 have not been established in the literature. Its alias names reflect its origin from the SYF2 splicing factor and its related sequence homology, but references to it as a molecular target or active protein are incorrect. Key context: - SYF2, the parent gene, is functionally important in splicing, cell cycle regulation, and cancer biology, but SYF2P1 is a non-coding element and not a drug target or receptor. - Only the SYF2 gene/protein (not SYF2P1) has established biological functions, disease roles, and potential as a therapeutic target. - If requested information for the functional SYF2 protein or gene is needed, refer to “Pre-mRNA-splicing factor SYF2” (not its pseudogene derivative).

Other names
CBPINPSYF2PCCNDBP1 interactor pseudogeneSYF2 homologRNA splicing factor pseudogene 1SYF2P1
02

Mechanism of action

None. As a non-coding pseudogene, SYF2P1 has no mechanism of action for drugs

03

Biological functions

None established for the pseudogene; pseudogenes may regulate gene expression of parent genes through mechanisms such as antisense RNA, siRNA, or competitive endogenous RNA, but no specific SYF2P1 function has been documented
04

Disease associations

Other. Generally, pseudogenes may regulate parental gene expression, sometimes modifying disease risk (e.g., cancer susceptibility), but no well-documented SYF2P1-specific disease association exists
05

Safety considerations

None. Pseudogenes do not pose direct therapeutic safety concerns, although gene conversion or regulation effects can theoretically influence disease processes indirectly
06

Interacting drugs

None
07

Biomarkers

None known

Beyond the preview

Go deeper on SYF2 pre-mRNA splicing factor pseudogene 1 (SYF2P1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on SYF2 pre-mRNA splicing factor pseudogene 1 (SYF2P1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call